The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC).

Martin  Wermke

Honoraria - Amgen; Boehringer Ingelheim; GWT; Janssen; Lilly; Merck Serono; Merck Serono; Novartis; SYNLAB

Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; ImCheck therapeutics; immatics; ISA Pharmaceuticals; Lilly; Novartis

Research Funding - Roche (Inst)

Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; GEMoaB; immatics; Merck Serono; Pfizer; Sanofi/Aventis

Enriqueta  Felip

Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BerGenBio; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; F. Hoffmann LaRoche; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Sanofi; Takeda; Turning Point Therapeutics

Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; F. Hoffmann LaRoche; Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; PeerVoice; Pfizer; Sanofi; Takeda; Touch Oncology

Research Funding - Merck (Inst); Merck KGaA (Inst)

Other Relationship - GRIFOLS

Yasutoshi  Kuboki

Honoraria - Bristol-Myers Squibb Japan; Lilly Japan; Taiho Pharmaceutical

Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Takeda

Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)

Travel, Accommodations, Expenses - Amgen

Daniel  Morgensztern

Stock and Other Ownership Interests  - Abbott Laboratories; Bristol-Myers Squibb/Medarex

Consulting or Advisory Role - Abbvie; Arcus Biosciences; Bristol-Myers Squibb; G1 Therapeutics; Lilly Medical; Mirati Therapeutics

Research Funding - Abbvie (Inst); Altum Pharmaceuticals (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Baxter (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); EpicentRx (Inst); Heat Biologics (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Surface Oncology (Inst); Y-mAbs Therapeutics (Inst)

Cyrus  Sayehli

Travel, Accommodations, Expenses - Boehringer Ingelheim; Lilly O.

Miguel F.  Sanmamed

Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Numab

Speakers' Bureau - MSD

Research Funding - Roche/Genentech (Inst)

Edurne  Arriola

Consulting or Advisory Role - Boehringer Ingelheim; Lilly; Sanofi

Speakers' Bureau - AstraZeneca; Bristol Myers Squibb Foundation; MSD Oncology; Roche

Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; Takeda

Zohra  Oum'Hamed

Employment - Boehringer Ingelheim

Eric  Song

Employment - Boehringer Ingelheim

Matus  Studeny

Employment - Boehringer Ingelheim

Valentina  Gambardella

No Relationships to Disclose